ProKidney Corp.
PROK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.05 | -2.25 | -0.01 |
| FCF Yield | -94.19% | -113.12% | -18.70% | -17.58% |
| EV / EBITDA | -1.76 | -1.54 | -3.27 | -13.13 |
| Quality | ||||
| ROIC | -45.12% | -38.23% | -30.14% | -195.07% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.66 | 0.52 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -25.42% | -57.43% | -42.25% | -81.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.45 | 3.39 | 0.36 |
| Interest Coverage | -20,408.44 | -12,626.83 | -711.66 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 11,752.04 | 0.00 | 0.00 | 0.00 |